8-K: Tempest Therapeutics Director Resignation
Director Resignation
Tempest Therapeutics announced the resignation of board member Ms. Simantov effective May 23, 2026.
Summary
- Ms. Simantov resigned from the Board of Directors of Tempest Therapeutics, Inc. effective May 23, 2026.
- The resignation is not due to any disagreement with the company regarding operations, policies, or practices.
- A separation agreement was executed, involving the waiver of accrued and unpaid retainer fees.
- Existing stock option awards and capital stock ownership remain unaffected by the resignation.
- Indemnification rights remain in effect for six years post-separation.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative event, as the company explicitly stated there were no disagreements involved in the director's departure.
Positives
- The resignation is explicitly stated as not being the result of any disagreement with company operations or policies, reducing uncertainty regarding internal governance.
Negatives
- The loss of a board member represents a reduction in board oversight capacity.
Risks
- Potential for board instability or the need to identify and onboard a replacement director to maintain appropriate committee composition.
Future Outlook
The company has not provided specific forward-looking guidance in this filing beyond the administrative transition of board membership.
Industry Context
StockSavvy.ai notes that board turnover in small-cap biotechnology firms is common, though investors typically monitor these changes for potential shifts in strategic direction or governance oversight.
Comparison to Industry Standards
- The separation agreement terms, including the waiver of fees and maintenance of indemnification, align with standard corporate governance practices for departing directors.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board of Directors | Ms. Simantov | None | 2026-05-23 | Resignation |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition | Resignation of a non-employee director. | 2026-05-23 | Minimal impact expected as the resignation is amicable. |
Stakeholder Impact
- Shareholders should note the change in board composition, though no immediate operational impact is indicated.
Next Steps
- Filing of the Separation Agreement as an exhibit to the upcoming Form 10-Q for the quarter ended June 30, 2026.
Key Dates
| Date | Description |
|---|---|
| 2026-03-30 | Filing of Annual Report on Form 10-K/A detailing director compensation. |
| 2026-05-23 | Effective date of Ms. Simantov's resignation from the Board. |
| 2026-05-29 | Date of the 8-K filing signature. |
Keywords
Tempest Therapeutics, TPST, Board Resignation, Corporate Governance, SEC Filing, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.